New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:36 EDTMRK, BIIB, SSNLFMerck, Samsung Bioepis enter collaboration agreement
Merck (MRK) and Samsung Bioepis, a joint venture between Samsung (SSNLF) Biologics and Biogen (BIIB), announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Under the terms of the agreement, the companies will collaborate on clinical development, regulatory filings and manufacturing. If approved, Merck will commercialize this candidate. This collaboration builds on the agreement made by the two companies in February 2013 to develop and commercialize multiple biosimilar candidates.
News For MRK;SSNLF;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 25, 2015
06:01 EDTSSNLFGlobal tablet shipments forecast at 221.4M units in 2015, DigiTimes says
Subscribe for More Information
February 24, 2015
10:43 EDTSSNLFMicron drop on Apple speculation presents buying opportunity, says Stifel
Subscribe for More Information
10:14 EDTSSNLFSamsung reportedly reaches deal with LG, Apple to supply DRAM, Korea Times says
Subscribe for More Information
05:17 EDTMRKMerck collaborates with Medicines Patent Pool to expand Raltegravir access
Subscribe for More Information
February 23, 2015
12:12 EDTSSNLFReport: Apple may be targeting next-gen experts from Samsung, Apple Insider says
Subscribe for More Information
08:57 EDTSSNLFT-Mobile releases teaser image of Samsung Galaxy S6, The Verge says
T-Mobile (TMUS) CEO John Legere released a teaser image of Samsung's (SSNLF) upcoming Galaxy S6 smartphone and also confirmed the carrier will offer the S6, reports The Verge, citing tweets and a T-Mobile website. The teaser image suggest a metal backing and curved screen edges on both sides of the phone. An official reveal is expected March 1. Reference Link
08:27 EDTMRKNGM Biopharmaceuticals to hold a teleconference
NGM Biopharm discusses the strategic collaboration with Merck to discover, develop and commercialize novel biologic therapeutics on a teleconference to be held on February 23 at 9:30 am. Webcast Link
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGM’s most recent financing. Merck will commit up to $250M to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
07:00 EDTSSNLFUnconfirmed price leak shows Samsung SUHD TVs starting at $2,499, CNet says
Subscribe for More Information
February 20, 2015
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTBIIBPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:08 EDTBIIBBiogen consortium identifies new ALS gene and signaling pathways
Subscribe for More Information
09:51 EDTSSNLFSamsung sees LoopPay tech built into smartphone hardware, TechCrunch says
Samsung will work to incorporate its recently-acquired LoopPay mobile payment technology directly into smartphone hardware, reports TechCrunch, citing statements by EVP and head of Samsung Mobile Injong Rhee. Rhee added that LoopPay is "compelling because of its coverage," as its technology allows it to work with roughly 90% of existing card payment terminals in U.S. stores. Samsung Innovation Center EVP David Eun noted the company will release new products incorporating the technology "in the near future" and hinted at the possibility of features like loyalty programs. Reference Link
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
February 18, 2015
15:43 EDTSSNLFSamsung to acquire digitial wallet start-up LoopPay
Subscribe for More Information
09:09 EDTSSNLFLionsgate and Samsung launch exclusive virtual reality experience
Lionsgate (LGF) and Samsung (SSNLF) have teamed up to create the exclusive virtual reality experience "Insurgent- Shatter Reality". The four-minute visual work of art is a fully-immersive, 360-degree narrative experience set in the world of the upcoming feature film The Divergent Series: Insurgent.
06:20 EDTSSNLFApple awarded patent for wireless head-mounted display, Financial Times reports
Subscribe for More Information
February 17, 2015
09:54 EDTSSNLFIDC says Xiaomi outpaced Samsung for 2014 Chinese smartphone sales
Research firm IDC reports that Xiaomi achieved a 12.5% market share in China for 2014, while Samsung took second place with 12.1%. Chinese Q4 sales for Samsung fell to fifth place among smartphone makers, at 7.9% market share, down from 18.8% in 4Q13. IDC expects roughly 10% YoY growth for the 2015 smartphone market in China.
06:48 EDTSSNLFSamsung to use $56B for growth, M&A aquisitions, Reuters says
Subscribe for More Information
05:53 EDTSSNLFSamsung to adopt 20nm process for 50% of 2015 DRAM output, DigiTimes says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use